Prescribe targeted oncology therapeutics considering panels of resistance genetic variants
Drugs are designed to bind to specific protein targets. Common genetic variation affects the drug binding site and action of the protein and can affect the efficacy of a drug, but this is generally not considered in the preclinical testing prior to a clinical trial. For the most popular precision oncology therapeutics, some resistance mutations are later identified and considered when prescribing a companion diagnostic test. However, there is no systematic approach to identify drug resistance. If this information were available to oncologists, it could be used to select among different drugs for more effective data-driven treatment.
Five Facts
- Genetic variation can produce drug resistance
- Little is known about drug resistance for precision oncology
- GMLs with and without drugs can identify all resistance mutations in a target for a drug
- Creates genetic profiles your team can compare fast
- Making drugs more effective
Powering precision prescriptions because patients and payers want drugs that work
Attempt to match a drug to a patient with a single genetic mutation
Heligenics matches many more patients using all mutations
We create genetic profiles for drugs that your team can compare quickly
Mapping out up to 95% of gene resistance mutations and their causative effects can now be done in months instead of years.